Anti-c-met antibody-drug conjugate comprising a camptothecin derivative

CL202601223A1Pending Publication Date: 2026-07-31CELLTRION INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202601223
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-10-18
Filing Date: 2026-04-15
Publication Date: 2026-07-31

Application Information

Patent Timeline

18 Oct 2024

Priority

15 Apr 2026

Application

CL202601223

31 Jul 2026

Publication

CL202601223A1

IPC: A61K47/68; A61P35/00; C07K16/28

CPC: A61K47/68; A61P35/00; C07K16/2863; C07K2317/92; C07K2317/33; A61K47/68037; A61K47/6849; A61K47/6851

Inventors: SEO Jimin; KIM Jongin

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention provides an antibody-drug conjugate having a structure in which a compound according to Chemical Formula 1, or a pharmaceutically acceptable salt thereof, stereoisomer, tautomer, prodrug, hydrate, solvate, or isotope-labeled analogue thereof, is linked to an anti-c-Met antibody via a linker. The antibody-drug conjugate according to the present invention can selectively impart the effect of the compound of Chemical Formula 1 to c-Met-expressing cancer cells.

Need to check novelty before this filing date? Find Prior Art